For: | Tsibouris P, Vlachou E, Isaacs PET. Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett’s esophagus. World J Gastrointest Pharmacol Ther 2014; 5(1): 27-39 [PMID: 24605249 DOI: 10.4292/wjgpt.v5.i1.27] |
---|---|
URL: | https://www.wjgnet.com/2150-5349/full/v5/i1/27.htm |
Number | Citing Articles |
1 |
Jusi Wang, Tingyu Chen, Weifeng Tang, Mingqiang Kang, Shuchen Chen. Associations of interleukin-4 and interleukin-4 receptor loci with esophageal squamous cell carcinoma susceptibility. International Immunopharmacology 2021; 97: 107659 doi: 10.1016/j.intimp.2021.107659
|
2 |
Magnus Halland, David Katzka, Prasad G Iyer. Recent developments in pathogenesis, diagnosis and therapy of Barrett's esophagus. World Journal of Gastroenterology 2015; 21(21): 6479-6490 doi: 10.3748/wjg.v21.i21.6479
|
3 |
Frederik Hvid-Jensen, Asbjørn Mohr Drewes. Should aspirin and PPIs be recommended for patients with Barrett's oesophagus?. The Lancet 2018; 392(10145): 362 doi: 10.1016/S0140-6736(18)31618-0
|
4 |
Omran Alsalahi, Anca D. Dobrian. Proton Pump Inhibitors: The Culprit for Barrett’s Esophagus?. Frontiers in Oncology 2015; 4 doi: 10.3389/fonc.2014.00373
|
5 |
Jennifer L. Schneider, Wei K. Zhao, Douglas A. Corley. Aspirin and Nonsteroidal Anti-Inflammatory Drug Use and the Risk of Barrett’s Esophagus. Digestive Diseases and Sciences 2015; 60(2): 436 doi: 10.1007/s10620-014-3349-2
|
6 |
Alessandra Pannunzio, Mauro Coluccia. Cyclooxygenase-1 (COX-1) and COX-1 Inhibitors in Cancer: A Review of Oncology and Medicinal Chemistry Literature. Pharmaceuticals 2018; 11(4): 101 doi: 10.3390/ph11040101
|
7 |
ABDULLAH K. ALTWAIRGI. Statins are potential anticancerous agents (Review). Oncology Reports 2015; 33(3): 1019 doi: 10.3892/or.2015.3741
|
8 |
Aleksandra M. Urbanska, Selvarangan Ponnazhagan, Masoud Mozafari. Pathology, Chemoprevention, and Preclinical Models for Target Validation in Barrett Esophagus. Cancer Research 2018; 78(14): 3747 doi: 10.1158/0008-5472.CAN-18-0206
|